![Tirzepatide reduces appetite, energy intake and fat mass in people with type 2 diabetes - Media Centre | EASD Tirzepatide reduces appetite, energy intake and fat mass in people with type 2 diabetes - Media Centre | EASD](https://d2t0unnjxes6lt.cloudfront.net/data/easd/data/talks/1167_879857/Slide1.jpg)
Tirzepatide reduces appetite, energy intake and fat mass in people with type 2 diabetes - Media Centre | EASD
![SURPASS-2: A Study Of Tirzepatide Versus Semaglutide Once Weekly As Add-on Therapy To Metformin In Participants With Type 2 Diabetes - My Endo Consult SURPASS-2: A Study Of Tirzepatide Versus Semaglutide Once Weekly As Add-on Therapy To Metformin In Participants With Type 2 Diabetes - My Endo Consult](https://endoconsult.b-cdn.net/wp-content/uploads/SURPASS2-NEW-2021.png)
SURPASS-2: A Study Of Tirzepatide Versus Semaglutide Once Weekly As Add-on Therapy To Metformin In Participants With Type 2 Diabetes - My Endo Consult
![Safety and efficacy of tirzepatide as an add-on to single oral antihyperglycaemic medication in patients with type 2 diabetes in Japan (SURPASS J-combo): a multicentre, randomised, open-label, parallel-group, phase 3 trial - Safety and efficacy of tirzepatide as an add-on to single oral antihyperglycaemic medication in patients with type 2 diabetes in Japan (SURPASS J-combo): a multicentre, randomised, open-label, parallel-group, phase 3 trial -](https://www.thelancet.com/cms/attachment/b455347c-542d-485e-b3e3-0d940e9b0524/gr1.gif)
Safety and efficacy of tirzepatide as an add-on to single oral antihyperglycaemic medication in patients with type 2 diabetes in Japan (SURPASS J-combo): a multicentre, randomised, open-label, parallel-group, phase 3 trial -
![Molecules | Free Full-Text | Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Mini-Review Molecules | Free Full-Text | Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Mini-Review](https://www.mdpi.com/molecules/molecules-27-04315/article_deploy/html/images/molecules-27-04315-g001.png)
Molecules | Free Full-Text | Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Mini-Review
![The most effective medication for weight loss and blood glucose stabilization: Tirzepatide - On Medicine The most effective medication for weight loss and blood glucose stabilization: Tirzepatide - On Medicine](https://blogs.biomedcentral.com/on-medicine/wp-content/uploads/sites/6/2023/01/tirzepatide.png)
The most effective medication for weight loss and blood glucose stabilization: Tirzepatide - On Medicine
![Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis | SpringerLink Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs00125-022-05715-4/MediaObjects/125_2022_5715_Figa_HTML.png)
Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis | SpringerLink
![Type 2 Diabetes Drug Tirzepatide (Mounjaro) Aids Weight Loss in People With Obesity: Study | Everyday Health Type 2 Diabetes Drug Tirzepatide (Mounjaro) Aids Weight Loss in People With Obesity: Study | Everyday Health](https://images.everydayhealth.com/images/mounjaro-weight-loss-study-alt-1440x810.png?sfvrsn=16c763ce_6)
Type 2 Diabetes Drug Tirzepatide (Mounjaro) Aids Weight Loss in People With Obesity: Study | Everyday Health
![Vasso's Corner: Tirzepatide, a new era for dual-treatment for type-2 diabetes and obesity - Neos Kosmos Vasso's Corner: Tirzepatide, a new era for dual-treatment for type-2 diabetes and obesity - Neos Kosmos](https://cdn1.neoskosmos.com/uploads/sites/2/2023/05/tirzepatide-PRINT_37952.jpg)
Vasso's Corner: Tirzepatide, a new era for dual-treatment for type-2 diabetes and obesity - Neos Kosmos
![Tirzepatide Slowed Progression of Chronic Kidney Disease in Patients with Type 2 Diabetes with Increased Cardiovascular Risk | ADA Tirzepatide Slowed Progression of Chronic Kidney Disease in Patients with Type 2 Diabetes with Increased Cardiovascular Risk | ADA](https://diabetes.org/sites/default/files/styles/16_9_medium_700x394/public/2022-06/Trizepatide%20-%20thumbnail.png)
Tirzepatide Slowed Progression of Chronic Kidney Disease in Patients with Type 2 Diabetes with Increased Cardiovascular Risk | ADA
![Mounjaro: New Tirzepatide diabetes jab that sparked diabetes row in US could get approved on NHS | The Independent Mounjaro: New Tirzepatide diabetes jab that sparked diabetes row in US could get approved on NHS | The Independent](https://static.independent.co.uk/2023/02/23/10/Eli%20Lilly%20drug%20Mounjaro%20Indycomp%20copy.jpg)
Mounjaro: New Tirzepatide diabetes jab that sparked diabetes row in US could get approved on NHS | The Independent
![FDA approves tirzepatide, Eli Lilly's new type 2 diabetes drug, and the company shares an estimated price FDA approves tirzepatide, Eli Lilly's new type 2 diabetes drug, and the company shares an estimated price](https://cardiovascularbusiness.com/sites/default/files/styles/top_stories/public/2022-05/tirzepatide_mounjaro_eli_lilly.jpg.webp?itok=gsx9Ec97)
FDA approves tirzepatide, Eli Lilly's new type 2 diabetes drug, and the company shares an estimated price
![Tirzepatide versus insulin glargine as second-line or third-line therapy in type 2 diabetes in the Asia-Pacific region: the SURPASS-AP-Combo trial | Nature Medicine Tirzepatide versus insulin glargine as second-line or third-line therapy in type 2 diabetes in the Asia-Pacific region: the SURPASS-AP-Combo trial | Nature Medicine](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41591-023-02344-1/MediaObjects/41591_2023_2344_Fig1_HTML.png)
Tirzepatide versus insulin glargine as second-line or third-line therapy in type 2 diabetes in the Asia-Pacific region: the SURPASS-AP-Combo trial | Nature Medicine
![Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial - The Lancet Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial - The Lancet](https://www.thelancet.com/cms/attachment/63fe4912-d57e-4c87-ad6b-1952000f93e1/gr1_lrg.jpg)